Exploring Biliary Tract Cancer: Top Takeaways From ASCO GI 2025 - Episode 2

The Importance of Early Biomarker Testing in Managing Advanced BTC

, , ,

Panelists discuss how comprehensive molecular profiling and biomarker testing are critical for guiding targeted therapy decisions in advanced biliary tract cancer (BTC), citing recent real-world data presented at ASCO GI that demonstrated improved outcomes with matched targeted therapies.

Video content above is prompted by the following:

  • What is the relevance and the importance of early biomarker testing in advanced BTC treatment now? Can you share highlights from the international collaborative study looking at the real-world impact of matched targeted therapy at ASCO GI this year?